1. Pink Sheet

US FDA User Fee Legislation: Is Sen. Burr’s ‘Clean’ Bill A Lifeline – Or A Wrench In The Works?

 
• By Derrick Gingery

Sen. Richard Burr introduces a reauthorization bill without any policy changes, even ones he previously endorsed, saying it’s the clearest path forward now.

SEN. BURR IS SUGGESTING THAT HIS STRIPPED-DOWN, ‘CLEAN’ USER FEE BILL MAY BE THE BEST WAY TO AVOID LAYOFF NOTIFICATIONS AT FDA.
SEN. BURR SUGGESTS THAT HIS STRIPPED-DOWN, ‘CLEAN’ USER FEE BILL MAY BE THE BEST WAY TO AVOID LAYOFF NOTIFICATIONS AT FDA. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

Sen. Richard Burr, R-NC, has shaken up and potentially reset negotiations on the reauthorization of the US Food and Drug Administration user fee programs with the introduction of a bill absent all policy riders.

User fee renewals are considered must-pass legislation because the funding is vital to FDA operations

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

More from Pathways & Standards

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.